Zacks Research Issues Positive Forecast for PBH Earnings

Prestige Consumer Healthcare Inc. (NYSE:PBH) – Research analysts at Zacks Research lifted their Q2 2026 earnings estimates for shares of Prestige Consumer Healthcare in a research report issued to clients and investors on Monday, June 16th. Zacks Research analyst R. Department now expects that the company will earn $1.19 per share for the quarter, up from their previous forecast of $1.18. The consensus estimate for Prestige Consumer Healthcare’s current full-year earnings is $4.50 per share. Zacks Research also issued estimates for Prestige Consumer Healthcare’s Q4 2026 earnings at $1.29 EPS, FY2026 earnings at $4.73 EPS and Q4 2027 earnings at $1.25 EPS.

Several other research analysts have also commented on the stock. Wall Street Zen upgraded shares of Prestige Consumer Healthcare from a “hold” rating to a “buy” rating in a research note on Saturday, May 17th. Royal Bank Of Canada upgraded shares of Prestige Consumer Healthcare to a “hold” rating in a research note on Thursday, May 8th. Three equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $93.33.

Prestige Consumer Healthcare Stock Performance

Shares of PBH opened at $83.51 on Wednesday. The company’s fifty day moving average is $83.85 and its 200-day moving average is $82.55. Prestige Consumer Healthcare has a 12 month low of $64.63 and a 12 month high of $90.04. The firm has a market cap of $4.13 billion, a price-to-earnings ratio of 19.47, a price-to-earnings-growth ratio of 2.51 and a beta of 0.45. The company has a quick ratio of 2.82, a current ratio of 4.20 and a debt-to-equity ratio of 0.55.

Prestige Consumer Healthcare (NYSE:PBH) last announced its quarterly earnings results on Thursday, May 8th. The company reported $1.32 EPS for the quarter, topping the consensus estimate of $1.30 by $0.02. Prestige Consumer Healthcare had a net margin of 18.86% and a return on equity of 12.87%. The company had revenue of $296.52 million for the quarter, compared to analyst estimates of $289.36 million. During the same quarter in the prior year, the business posted $1.02 EPS. Prestige Consumer Healthcare’s quarterly revenue was up 7.0% on a year-over-year basis.

Institutional Trading of Prestige Consumer Healthcare

Several large investors have recently modified their holdings of PBH. Kayne Anderson Rudnick Investment Management LLC bought a new stake in shares of Prestige Consumer Healthcare during the 4th quarter worth $84,932,000. Raymond James Financial Inc. bought a new stake in Prestige Consumer Healthcare in the 4th quarter valued at $42,593,000. Norges Bank bought a new stake in Prestige Consumer Healthcare in the 4th quarter valued at $40,009,000. Bessemer Group Inc. boosted its holdings in Prestige Consumer Healthcare by 10,053.1% in the 4th quarter. Bessemer Group Inc. now owns 295,050 shares of the company’s stock valued at $23,041,000 after purchasing an additional 292,144 shares during the period. Finally, Invesco Ltd. boosted its holdings in Prestige Consumer Healthcare by 24.7% in the 1st quarter. Invesco Ltd. now owns 1,321,800 shares of the company’s stock valued at $113,635,000 after purchasing an additional 261,537 shares during the period. 99.95% of the stock is owned by institutional investors.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.